

Supplementary Table 3. Common genes between our results and published inherited ovarian literature

Common with	Gene Symbol (HUGO)	Entrez Gene ID	Description	Cytoband (HUGO)	RNA Source	Comparison	Literature Data	P-value or Fold change	Method	Reference
NM-M1 contrast	<i>PTGS2</i>	5743	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	1q25.2-q25.3	TOV (tissue), IOSEs	TOV (F- & NF) vs. IOSEs	TOV (-)	≥2 fold change	*MA	Jazaeri et al. (2002) J Natl Can Inst; 94 (13), 990-1000
	<i>SAA2</i>	6289	serum amyloid A2	11p15.1-p14	NOSES (#PC)	F-NOSEs1 vs. NF-NOSEs	F-NOSEs1 (-)	≥2 fold change	*MA	Bellacosa et al. (2010) Cancer Prev Res; 3:48-61.
	<i>SAA1</i>	6288	serum amyloid A1	11p15.1	NOSES (#PC)	F-NOSEs1 vs. NF-NOSEs	F-NOSEs1 (-)	≥2 fold change	*MA	Bellacosa et al. (2010)
NM-M2 contrast	<i>MPI</i>	4351	Mannose phosphate isomerase	15q22-qter	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
M1-M2 contrast	<i>BCL2</i>	596	B-cell CLL/ lymphoma 2	18q21.3	F-NOSES (°SE), BOVs, TOV(°P-E tissues)	(F-NOSEs or BOVs) vs. TOVs	TOV (-)	< 0.001	**IHC	Kerner et al. (2005) Gynecologic Oncology; 99, 367-375
	<i>ELF4</i>	2000	E74-like factor 4 (ets domain transcription factor)	Xq26	TOV (tissue)	F-TOV1 vs. NF-TOV	F-TOV1 (+)	<0.005	MA	Jazaeri et al. (2004). J Translational Med; 2(32), 1-8
	<i>MPI</i>	4351	mannose phosphate isomerase	15q22-qter	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>PAK2</i>	5062	p21 (CDKN1A)-activated kinase 2	3	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>PTGS2</i>	5743	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	1q25.2-q25.3	TOV, IOSEs	TOV (F- and NF) vs. IOSEs	TOV (-)	≥2 fold change	MA	Jazaeri et al. (2002)

	<i>TCF4</i>	6925	transcription factor 4	18q21.1	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV2 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>SAA2</i>	6289	serum amyloid A2	11p15.1-p14	NOSES (#PC)	F-NOSEs1 vs. NF-NOSEs	F-NOSEs1 (-)	≥2 fold change	*MA	Bellacosa et al. (2010).
	<i>SAA1</i>	6288	serum amyloid A1	11p15.1	NOSES (#PC)	F-NOSEs1 vs. NF-NOSEs	F-NOSEs1 (-)	≥2 fold change	*MA	Bellacosa et al. (2010)
	<i>WAS</i>	7454	Wiskott-Aldrich syndrome (eczema-thrombocytopenia)	Xp11.4-p11.21	TOV (tissue)	F-TOV1 vs. NF-TOV	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
NM1-TM1 contrast	<i>HGF</i>	3082	hepatocyte growth factor (hepatopoietin A; scatter factor)	7q21.1	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>HSPB1</i>	3315	heat shock 27kDa protein 1	7q	IOSEs	F-IOSEs-1 vs. NF-IOSEs	F-IOSEs1(-)	1.7 fold-change	†MALDI-TOF MS	Smith-Beckerman et al. (2005). Molecular and Cellular Proteomics ; 4,156-168.
	<i>LCN2</i>	3934	lipocalin 2 (oncogene 24p3)	9q34	TOV (tissue)	F-TOV1 vs. NF-TOV	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>MPI</i>	4351	mannose phosphate isomerase	15q22-qter	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>PAK2</i>	5062	p21 (CDKN1A)-activated kinase 2	3	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>PON1</i>	5444	paraoxonase 1	7q21.3	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV2 (+)	<0.0001	MA	Jazaeri et al. (2002)
	<i>PRKG1</i>	5592	protein kinase, cGMP-dependent, type I	10q11.2	F-NOSE1 & NF-NOSES #PC, IOSEs, TIOSEs & TOVs	NOSEs vs. IOSEs vs. TIOSES & TOVs	High in NOSEs; low in IOSEs; absent in TIOSES	<0.001	‡WB	Wong et al. (2001) Gynecologic Oncology; 82, 305-311
	<i>PTGS2</i>	5743	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	1q25.2-q25.3	TOV, IOSEs	TOV (F- & NF) vs. IOSEs	TOV (-)	≥2 fold change	MA	Jazaeri et al. (2002)
	<i>TAGLN2</i>	8407	transgelin 2	1q21-q25	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)

<i>TCF4</i>	6925	transcription factor 4	18q21.1	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV2 (+)	<0.0001	MA	Jazaeri et al. (2002)
<i>UBAP2L</i>	9898	ubiquitin associated protein 2-like	1q21.3	TOV (tissue)	F-TOV1 vs. F-TOV2	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
<i>WAS</i>	7454	Wiskott-Aldrich syndrome (eczema-thrombocytopenia)	Xp11.4-p11.21	TOV (tissue)	F-TOV1 vs. NF-TOV	F-TOV1 (+)	<0.0001	MA	Jazaeri et al. (2002)
<i>KRT18</i>	3875	Keratin 18	12q13	NOSEs (FH & NFH) PC	F-NOSEs2 vs. NF-NOSEs	F-NOSEs2 (-)	0.35 fold-change	MA	Bellacosa et al (2010)

NOSE: morphologically normal ovarian surface epithelium, TOV: tumor of ovary, TOV1: TOV from a *BRCA1* carrier, TOV2: TOV from a *BRCA2* carrier.

IOSE: immortalised ovarian surface epithelium cell line, TIOSE: Tumoral-IOSE.

F-NOSE1: NOSE from a *BRCA1* mutation carrier, F-NOSE2: NOSE from a *BRCA2* mutation carrier.

NF: Non-familial (without a *BRCA1* or *BRCA2* mutation), F: Familial with a *BRCA1* or *BRCA2* mutation.

*MA: Microarray, **IHC: Immunohistochemistry, ‡WB: Western Blot, °P-E: Paraffin-Embedded, °°SE: Surface epithelium, #PC: Primary cultures.

(+): increased level of expression, (-): decreased level of expression.